The bone morphogenetic protein (BMP)-SMAD signaling pathway is a key transcriptional regulator of hepcidin in response to tissue iron stores, serum iron, erythropoietic drive and inflammation to increase the iron supply when needed for erythropoiesis, but to prevent the toxicity of iron excess. Recently, BMP2 was reported to play a non-redundant role in hepcidin regulation in addition to BMP6. Here, we used a newly validated BMP2 ELISA assay and mice with a global or endothelial conditional knockout (CKO) of Bmp2 or Bmp6 to examine how BMP2 is regulated and functionally contributes to hepcidin regulation by its major stimuli. Erythropoietin (EPO) did not influence BMP2 expression in control mice, and still suppressed hepcidin in Bmp2 CKO mice. Lipopolysaccharide (LPS) reduced BMP2 expression in control mice, but still induced hepcidin in Bmp2 CKO mice. Chronic dietary iron loading that increased liver iron induced BMP2 expression, whereas acute oral iron gavage that increased serum iron without influencing liver iron did not impact BMP2. However, hepcidin was still induced by both iron loading methods in Bmp2 CKO mice, although the degree of hepcidin induction was blunted relative to control mice. Conversely, acute oral iron gavage failed to induce hepcidin in Bmp6 −/− or CKO mice.
| INTRODUCTION
The participation of iron in numerous physiological activities makes it indispensable for nearly all living organisms. Iron deficiency impairs cell growth and survival, is a major cause anemia, and represents a significant global health concern.
1,2 Excess iron accumulation, however, generates free radicals via the Fenton reaction that can lead to cell damage, 3 as seen in hereditary hemochromatosis and iron loading anemias. 4, 5 Therefore, iron metabolism must be carefully maintained and regulated.
Systemic iron levels are governed by the liver hormone hepcidin (HAMP), which promotes the degradation of iron exporter ferroportin in enterocytes, macrophages and hepatocytes to control iron entry into the plasma. 6 Inactivating mutations in HAMP or mutations in SLC40A1 (encoding ferroportin) that interfere with hepcidin binding lead to the iron overload disorder hereditary hemochromatosis. 7, 8 Moreover, the mechanism of action of several other genes, including HFE, HJV (encoding hemojuvelin), TFR2 (encoding transferrin receptor 2), and BMP6 (encoding bone morphogenetic protein [BMP] 6), whose mutations have been identified in humans to associate with iron overload depends on their ability to appropriately induce hepcidin expression in response to iron. [9] [10] [11] [12] Whereas iron induces hepcidin as a feedback mechanism to prevent iron overload, iron deficiency or acute blood loss suppress hepcidin expression to ensure adequate iron supply for red blood cell production. Erythrocyte precursor derived erythroferrone plays a critical role in hepcidin suppression by erythropoietic drive, 13 and excess erythroferrone production and consequent hepcidin deficiency contribute to iron overload in diseases of
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ineffective erythropoiesis such as β-thalassemia. 14 In the context of many infections, hepcidin transcription is increased by inflammatory cytokines to limit iron availability to harmful microorganisms; however, excess induction of hepcidin in the setting of chronic inflammatory diseases also contributes to iron restricted erythropoiesis and anemia. 15 The BMP-SMAD signaling pathway is the central transcriptional regulator of hepcidin and is critically involved in controlling hepcidin expression in response to iron. 16 Tissue iron loading increases BMP6 production in liver endothelial cells, 17 which initiates a signaling cascade by binding to hepatocyte BMP type I and type II receptors and the co-receptor HJV and subsequently activates transcription factors SMAD1/5/8 and SMAD4 to translocate into the nucleus for hepcidin transcription. 15 Acute increases in serum iron, presumably in the form of diferric transferrin, independently increase hepcidin expression even in the absence of tissue iron loading. 18, 19 Although acute serum iron loading without tissue iron loading activates the downstream SMAD1/5/8 signaling cascade, it does not impact liver BMP6 mRNA expression. 18 Moreover, genetic ablation of the Hfe localizing protein beta-2-microglublin (B2m) or Tfr2, which are implicated in sensing serum diferric transferrin and functionally intersect with the SMAD1/5/8 signaling cascade to induce hepcidin production, 20, 21 worsens the iron overload phenotype of Bmp6 −/− mice. 22 These data raise the possibility that another BMP ligand may play a role in hepcidin induction by serum iron levels via HFE and TFR2.
The BMP-SMAD pathway has also been implicated in hepcidin regulation by erythropoietic drive and inflammation. Erythropoietin (EPO) and erythroferrone decrease SMAD1/5/8 phosphorylation in hepatocytes, and their ability to suppress hepcidin expression is completely abrogated in hepatocyte-specific Smad1/5 conditional knockout (CKO) mice. 23 However, erythropoietin retains the ability to suppress hepcidin in Bmp6 −/− mice. 24, 25 In a similar vein, inflammation induces SMAD1/5/8 phosphorylation in hepatocytes, but retains the ability to stimulate hepcidin in Bmp6 −/− mice. 26 These data also suggest the possibility that erythropoietic drive and/or inflammation may also regulate the production of or response to another BMP family ligand to control hepcidin production.
Recently, we and others demonstrated that independent of BMP6, BMP2 also plays an essential role in hepcidin regulation and iron homeostasis since mice with an endothelial CKO of Bmp2 exhibit hepcidin deficiency and iron overload, similar to mice with a global or Table S1 . Standard curves were run in each qRT-PCR reaction, which were validated as linear over the range of expression seen in all samples. Transcript levels were determined as previously described 28 and are reported as -ΔCt = Ct Rpl19 reference -Ct target. The fold change is derived from 2 -ΔΔCt .
| Iron analysis
Serum iron and unsaturated iron binding capacity were measured by colorimetric assay (Pointe Scientific, Canton, Michigan) to calculate transferrin saturation according to manufacturer's instructions. Tissue nonheme iron concentrations (in μg/g wet weight) were determined as described previously. 23 
| BMP2 enzyme-linked immunosorbent assay
Serum BMP2 was measured using BMP2 ELISA Kit (R&D Systems DBP200, Minneapolis, Minnesota) in 1:2 dilution according to manufacturer's instructions. Liver samples were homogenized in ice-cold PBS containing 0.05% sodium azide, 0.5% Triton X-100, 1× complete mini protease inhibitor Cocktail (Roche, Basel, Switzerland) and 1X Halt Phosphatase Inhibitor Cocktail (Thermo Scientific, Waltham, Massachusetts).
| Statistics
Statistical significance was determined by 2-tailed Student's t test or one-way analysis of variance (ANOVA) with Tukey's post hoc test for pairwise multiple comparisons using Prism 7 (GraphPad, La Jolla, California). P < 0.05 was considered significant.
3 | RESULTS
| Validation of a BMP2 ELISA
To investigate how BMP2 protein expression is regulated by the major stimuli known to control hepcidin production, we first validated a commercially available BMP2 ELISA using endothelial Bmp2 CKO (Bmp2 in Cre-control mice (4.7-fold, Figure 3F ), similar to prior report for Bmp6 −/− mice. 26 Although our study was not powered to compare genotype effects in addition to treatment effects, the maximal Hamp mRNA levels achieved appeared to be lower in the Cre+ mice compared to Cre-controls in the setting of lower baseline Hamp mRNA, similar to the prior report for Bmp6 −/− mice. 26 
| Serum and liver BMP2 protein are regulated by chronic changes in dietary iron
We previously demonstrated that chronic changes in dietary iron significantly regulate liver Bmp2 mRNA expression, although to a lesser extent than Bmp6. 17 To examine whether chronic changes dietary iron also regulate BMP2 protein expression, serum and liver BMP2 protein levels were quantitated by the validated BMP2 ELISA from Figure 1 in wildtype mice treated with a low iron (2-6 ppm), an iron sufficient diet (Control, 48 ppm) or a high iron diet (2% carbonyl) for 3 weeks. Serum and liver iron concentrations were measured to confirm dietary iron effects ( Figure 3A,B) . Liver Bmp2 mRNA was significantly reduced by a low iron diet and increased by a high iron diet ( Figure 3C ) similar to our prior study. 17 Liver BMP2 protein levels were also significantly reduced by the low iron diet, although no significant increase in liver BMP2 protein expression was seen in mice treated with the high iron diet ( Figure 3D ).
Serum BMP2 levels were significantly increased by a high iron diet with a trend toward reduced levels in mice treated with a low iron diet ( Figure 3E ). In the overall population, there was a significant correlation between liver iron content and serum BMP2 levels (R = 0.899, P < 0.001). A survey of other tissues showed that although a low iron diet reduced Bmp2 mRNA in the bone marrow and pancreas, and a high iron diet increased Bmp2 mRNA in the spleen, the liver was the only tissue tested where Bmp2 mRNA levels were both reduced by a low iron diet and increased by a high iron diet (Supplemental Figure S2 ). ;Tek-Cre+ mice. Animals were then either kept on the low iron diet for 1 more week or switched to the house diet that contains 380 ppm iron. Mice switched to the house diet had significantly increased liver iron levels compared to mice kept on the low iron diet ( Figure 3F ) with associated increases in liver Bmp6 mRNA ( Figure 3G ).
In the Cre-control mice, Hamp mRNA was greatly induced by dietary iron by 240-fold, consistent with prior observations ( Figure 3H ). 23, 28 In ;Tek-Cre+ mice, Hamp mRNA was still significantly induced by 226-fold. 26 However, the maximal hepcidin levels achieved were lower in Cre+ mice compared to Cre-mice, particularly when considered relative to the higher degree of liver iron loading in the Cre+ mice ( Figure 3I ). Together, these data suggest that although BMP2 facilitates ;Tek-Cre+ and littermate Cre-control male (blue circles, n = 3-5 per group) and female (red triangles, n = 6-8 per group) mice at 6 weeks of age were injected with PBS or EPO (200 U per mouse) and tissues were collected after 15 hours to determine relative (C) bone marrow erythroferrone (Erfe), (D) liver Bmp2, and (G) liver hepcidin (Hamp) mRNA levels by qRT-PCR. Transcript levels were normalized to Rpl19. (E) Liver and (F) serum BMP2 protein levels in female Cre-animals were determined by ELISA. Values represent mean AE SEM. **P < 0.01, ***P < 0.001 relative to the respective Cre-controls or PBS-treated controls of the same genotype by Student's t test. 
| Hepcidin induction by acute serum iron loading requires BMP6, but not BMP2
Chronic changes in dietary iron increases both serum and liver iron levels, which are known to independently stimulate hepcidin transcription. 18, 19 We next sought to investigate whether an isolated increase in serum iron and transferrin saturation regulates serum or liver BMP2 expression and whether BMP2 or BMP6 is required for hepcidin induction in this context. Figure S3 ).
These data suggest that neither BMP2 nor BMP6 is regulated by serum iron; however, BMP6 is required for hepcidin induction by serum iron. In contrast, although the presence of BMP2 facilitates maximal hepcidin induction, serum iron has a residual ability to induce hepcidin in the absence of BMP2.
| DISCUSSION
The BMP-SMAD signaling pathway is a major transcriptional regulator of hepcidin expression. 31 This pathway not only regulates hepcidin transcription in response to serum and tissue iron levels, 18 but also intersects with other major hepcidin regulatory stimuli including erythropoietic drive 23 and inflammation. 32,33 BMP2 was recently identified as a key ligand in hepcidin and iron homeostasis regulation 17, 27 in addition to BMP6. 34 , 35 Here, we define how BMP2 expression is controlled ;Tek-Cre+ and littermate Cre-control male (blue circles, n = 6-8 per group) and female (red triangles, n = 4-5 per group) mice at 6 weeks of age were injected with PBS or LPS (1 mg per kg body weight) and sacrificed after 6 hours. Livers were collected to determine (A) Il6, (B) Bmp2, (E) Bmp6 and (F) Hamp mRNA levels. Transcripts measured by qRT-PCR were normalized to Rpl19. (C) Liver and (D) serum BMP2 protein levels in Cre-animals were determined by ELISA. Values represent mean AE SEM. *P < 0.05, **P < 0.01, ***P < 0.001 relative to the PBS-treated controls of the same genotype by Student's t test. Fold-change relative to PBS treated controls of the same genotype as calculated by 2 -ΔΔCt are reported in panel F [Color figure can be viewed at wileyonlinelibrary.com]
by major hepcidin regulatory stimuli and the functional contribution of BMP2 relative to BMP6 in hepcidin regulation by these stimuli.
Using a newly validated BMP2 ELISA, our results demonstrated that BMP2 protein levels were regulated proportionally to chronic changes in body iron loading to some extent both in the circulation and liver. Interestingly, the induction of BMP2 by a high iron diet was only detected in circulation, not in the liver, whereas the reduction of BMP2 by a low iron diet was more readily detected in the liver than circulation. Total liver Bmp2 mRNA was reduced by a low iron diet and induced by a high iron diet, suggesting that iron does modulate liver BMP2 production. A similar regulation of Bmp2 mRNA by iron was previously reported in liver endothelial cells, 17 which are the predominant cells in the liver responsible for BMP2 production. 17, 27 One explanation for why we did not detect an increase in liver BMP2 protein by a high iron diet despite an increase in liver Bmp2 mRNA and circulating BMP2 protein could be that BMP2 is more rapidly secreted or some hematopoietic cells. 30 However, a survey of other tissues found that although a low iron diet reduced Bmp2 in the bone marrow and pancreas and a high iron diet induced Bmp2 in the spleen, the liver was the only organ tested where Bmp2 mRNA was both reduced by a low iron diet and increased by a high iron diet. Thus, the liver is most likely the predominant source of circulating BMP2 in response to changes in dietary iron, although we cannot definitively rule out a contribution from another source. Future experiments will be needed to test whether iron loading impacts liver BMP2 secretion.
Results from the Bmp2 fl/fl
;Tek-Cre+ mice demonstrated that BMP2 is required for optimal hepcidin induction in response to chronic dietary iron loading. Although the fold induction of hepcidin was only marginally ;Tek-Cre+ and littermate Cre-controls were weaned to a low iron diet for 3 weeks and then either switched to the house diet (380 ppm iron) or kept on a low iron diet for 1 more week (n = 6 per group, 2-4 of each sex). (A) Serum iron and (B,F) liver iron levels were quantified by colorimetric assay. (C) Liver Bmp2, (G) Bmp6, and (H) Hamp mRNA levels were measured by qRT-PCR and normalized to Rpl19. (D) Liver and (E) serum BMP2 protein levels were quantified by ELISA. (I) Liver Hamp normalized to Rpl19 mRNA relative to liver iron content was calculated for mice switched to the house diet. Values represent mean AE SEM. *P < 0.05, **P < 0.01, ***P < 0.001 relative to mice treated with a control diet by one-way ANOVA with Tukey's post hoc test (panels A-E), a low iron diet of the same genotype by Student's t test (panels F-H) or Cre-mice switched to a house diet by Student's t test (panel I Each ligand individually appears to retain some residual ability to stimulate hepcidin in this context, but both are required for a maximal effect.
Previous studies have demonstrated that in addition to chronic changes in iron stores, acute changes in serum iron levels (presumably by holo-transferrin) independently regulate hepcidin expression. 18, 19 Although chronic dietary iron loading and deficiency modulated BMP2 expression, BMP2 levels were not changed by an isolated increase in serum iron and transferrin saturation in response to oral iron gavage. Although a prior report suggested that liver BMP2 may be modulated by apo-transferrin administration, we were not able to validate the specificity of BMP2 antibody used in that study using our ;Tek-Cre+ mice (data not shown). 36 A similar lack of modulation by serum iron was also seen for BMP6, at least at the mRNA level, as previously reported. 18 Thus, whereas both BMP6 and BMP2 expression are modulated by iron stores and thus contribute to hepcidin regulation in this context, neither BMP2 nor BMP6 levels are modulated by serum iron or transferrin saturation in response to oral iron gavage. One caveat to this conclusion is that assays are not read- ;Tek-Cre+ mice could suggest an alternative mechanism for EPO-mediated hepcidin suppression in these mice.
Notably, EPO-mediated suppression of SMAD5 phosphorylation and
Id1 mRNA was relatively modest and not always reproducible in wildtype mice, which also raises the possibility of an alternative pathway. 13, 23, 24 However, a caveat to these conclusions is that BMP effects on SMAD5 phosphorylation and Id1 expression are less robust and occur with different kinetics compared with BMP effects on hepcidin, and therefore these readouts may not be sensitive enough to detect changes in SMAD pathway activity in this system. Interestingly, a recent report published during the preparation of this manuscript demonstrated that erythroferrone selectively inhibits hepcidin induction by BMP6, BMP5, and BMP7 ligands, but not BMP2, in cell culture. 37 These data are consistent with a functional role for BMP-SMAD signaling in hepcidin regulation by erythroferrone, but a dispensable role for BMP2. However, 2 previous studies reported that hepcidin is still suppressed by EPO in Bmp6 knockout mice, 24, 25 suggesting that BMP6 is not required for hepcidin suppression by erythropoietic drive in vivo. Future studies will be needed to understand the precise role of the BMP-SMAD pathway and potential alternative pathways in hepcidin suppression by erythroferrone and erythropoietic drive in vivo.
Inflammatory cytokines stimulate hepcidin production predominantly via interleukin 6 (IL6) and a STAT3 binding element on the hepcidin promoter. 15 Prior studies have suggested that the inflammatory pathway requires BMP-SMAD signaling because IL6 loses the ability to stimulate hepcidin in Alk3 or Smad4 hepatocyte CKO mice. 32, 33 Moreover, in vitro studies suggested an interaction at the level of the hepcidin promoter via the STAT3 binding element and a proximal BMP responsive SMAD binding element. 38 Here, we demonstrated that LPS retains its potency to induce hepcidin in the absence of BMP2 and similar findings have been reported for BMP6. 26 However, loss of either ligand does reduce basal hepcidin expression 17, 28, 34, 35 and thereby tends to lower the maximal hepcidin levels reached in response to inflammation. Thus, BMP ligands influence hepcidin levels in the context of inflammation by altering the basal setpoint. Notably, endogenous BMP2 and BMP6 expression are reduced by LPS in control mice, which was also previously shown for the BMP co-receptor HJV, 39 suggesting that dampening iron-responsive hepcidin mediators may be desirable under conditions of inflammation.
In summary, our results have validated a commercial BMP2 ELISA assay and demonstrated that BMP2 is regulated concordantly with hepcidin by tissue iron, but not serum iron, erythropoietic drive, or inflammation. Thus, regulation of BMP2 expression, in addition to BMP6, is one mechanism by which tissue iron levels impact hepcidin production. However, BMP2 is at least partially dispensable for hepcidin regulation by all of its major stimuli, whereas BMP6 is absolutely required for hepcidin induction by serum iron. These findings demonstrate important distinctions between the functional roles of BMP2 and BMP6 and provide new insights into how the liver senses iron levels and integrates this with other signals to regulate hepcidin production and iron homeostasis.
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